IFIT2 and breast cancer: Finally, a hazard ratio analysis of patients with ER+ BC found a significantly increased risk for lower survival with increased tumor expression of IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT2, IFIT3, ISG15, MX1, OAS1, and OASL (Supplemental Figure 8D).